Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Dermatology · Mycosis Fungoides

Skin-Directed Therapies and Early Management

At a Glance

For early mycosis fungoides, treatment usually focuses on the skin with creams, gels, phototherapy, or targeted radiation to clear lesions and relieve itching. Deeper variants may need PUVA or radiation, and regular follow-up is important because relapse can occur.

For most people with early-stage Mycosis Fungoides (MF), the primary goal of treatment is to clear the skin and manage symptoms like itching while avoiding the side effects of systemic “internal” chemotherapy. This is achieved through skin-directed therapies, which target the cancer exactly where it lives: in the skin [1][2].

Topical Treatments: The First Line

Topical therapies are often the starting point for patients with limited patches or plaques.

  • Topical Corticosteroids: These are the most common first-line treatment. They work by reducing the inflammation and the “homing” of T-cells to the skin. In one study, about 73% of patients saw improvement, though only about 33% achieved complete clearance [3]. Safety note: Prolonged or potent topical steroid use can cause skin thinning and requires strict adherence to prescriber instructions.
  • Chlormethine (Nitrogen Mustard) Gel: This is a topical chemotherapy gel applied directly to the skin. Unlike internal chemotherapy, it stays local and does not enter the bloodstream in significant amounts.
    • The “Slow Build”: It can take months to see a full response; peak effectiveness in trials often wasn’t reached until about month 10 [4].
    • Safety and Side Effect Management: You must handle chlormethine safely, avoid eyes and mucous membranes, and follow product-specific storage instructions. The most common side effect is contact dermatitis (a red, itchy rash caused by irritation). Doctors often manage this by directing a less frequent application (such as every other day) and prescribing topical steroids to calm irritation [5].

Phototherapy: Light as Medicine

Phototherapy uses specific wavelengths of ultraviolet (UV) light to kill the cancerous T-cells in the skin. This usually requires visiting a clinic 2–3 times per week [6]. You must follow the clinic’s exposure plan, never change sessions independently, and report severe redness or blistering.

  • Narrowband UVB (NB-UVB): This is the most common form of light therapy. It is generally very effective for thin, scaly patches. It does not require any medications before treatment [7][8].
  • PUVA (Psoralen + UVA): This involves taking a medicine called psoralen (either as a pill or a soak) that makes the skin more sensitive to light, followed by exposure to long-wave UVA light.
    • Deeper Penetration: Because UVA light travels deeper into the skin than UVB, PUVA is often preferred for thicker plaques or certain variants [9].
    • Safety Requirements: PUVA requires strict photosensitivity precautions, mandatory eye protection, and sun avoidance. Psoralen can cause nausea and medication interactions. PUVA carries a cumulative risk for developing secondary skin cancers over time [10][11].

Why Variants Change the Strategy

If your diagnosis includes “Folliculotropic” or “Syringotropic” MF, your treatment plan may look different. In these variants, the cancerous cells reside deeper in the skin—around hair follicles or sweat glands—than in classic MF [12].

Because these cells are “hiding” deeper down, superficial treatments like NB-UVB or standard steroid creams may not reach them effectively [13]. For these cases, your doctor might recommend:

  1. PUVA: For its deeper light penetration [14].
  2. Localized Radiotherapy: This uses targeted X-rays to treat specific, stubborn areas. It is highly effective, with complete response rates often exceeding 90% in the treated area [14][15].
  3. Total Skin Electron Beam Therapy (TSEBT): For widespread or deeper disease that hasn’t responded to other treatments, TSEBT uses a specialized form of radiation to treat the entire skin surface at a shallow depth [16][17]. Both forms of radiation can cause burns, skin changes, and hair loss.

Maintenance and Long-Term Care

MF is often a chronic condition. Even after your skin clears (complete remission), relapse can occur. Some doctors may suggest a “maintenance” phase—using phototherapy or topical treatments less frequently—to keep the disease from returning. In certain studies, maintenance phototherapy extended remission significantly [18][19]. However, maintenance phototherapy is not universally recommended due to cumulative UV exposure risks. Regardless of the treatment, regular follow-up with your dermatologist is essential to monitor for any new spots or changes in the skin [11].

Common questions in this guide

What treatments are usually used first for early mycosis fungoides?
Early mycosis fungoides with limited patches or plaques is often treated with therapies directed at the skin, such as topical corticosteroids, chlormethine gel, or phototherapy. The goal is to clear the skin and control itching while limiting exposure to systemic chemotherapy.
Is narrowband UVB or PUVA better for mycosis fungoides?
Narrowband UVB is commonly used for thin, scaly patches. PUVA reaches deeper into the skin and may be preferred for thicker plaques or deeper variants such as folliculotropic or syringotropic mycosis fungoides. Your clinician will choose based on the depth and distribution of your lesions and your safety needs.
How long does chlormethine gel take to work, and what side effects can it cause?
Chlormethine gel may take several months to produce its full effect, and studies have often found peak responses around 10 months. The most common side effect is contact dermatitis, a red or itchy irritated rash. Your clinician may reduce how often you apply it and recommend a topical steroid to calm the irritation.
How often is phototherapy needed for mycosis fungoides?
Phototherapy commonly requires visiting a clinic two to three times each week for several months, although the schedule depends on your treatment plan. Follow the clinic's exposure instructions and do not change sessions on your own. Report severe redness or blistering promptly.
When might radiation be used for mycosis fungoides?
Localized radiotherapy may be used for specific stubborn areas, while total skin electron beam therapy may be considered for widespread or deeper disease that has not responded to other treatments. Radiation can cause temporary or lasting skin changes, burns, and hair loss, so your treatment team will discuss the risks.
Can mycosis fungoides return after the skin clears?
Yes, mycosis fungoides can relapse even after the skin reaches complete remission. Some clinicians recommend less frequent phototherapy or topical treatment as maintenance, but this is not appropriate for everyone because repeated ultraviolet exposure has risks. Regular dermatology follow-up helps monitor for new or changing spots.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on mycosis fungoides variant.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my skin involvement superficial enough for Narrowband UVB (NB-UVB), or do my lesions have 'folliculotropic' features that suggest PUVA or radiation would be more effective?
  2. 2.If we start chlormethine gel, what is the best strategy to manage potential contact dermatitis—should we start with a lower frequency of application?
  3. 3.How many sessions of phototherapy should I expect before we evaluate whether it is working?
  4. 4.Given my disease distribution, would I benefit more from localized radiotherapy on specific spots or Total Skin Electron Beam Therapy (TSEBT)?
  5. 5.If I achieve a complete response, do you recommend a maintenance schedule for phototherapy or topical treatments to prevent a relapse?

References

References (19)
  1. 1

    New developments in skin-directed treatments of cutaneous T-cell lymphoma.

    Amitay-Laish I, Hodak E

    Presse medicale (Paris, France : 1983) 2022; (51(1)):104125 doi:10.1016/j.lpm.2022.104125.

    PMID: 35562084
  2. 2

    NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.

    Mehta-Shah N, Horwitz SM, Ansell S, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2020; (18(5)):522-536.

    PMID: 32380458
  3. 3

    Response to topical corticosteroid monotherapy in mycosis fungoides.

    Kartan S, Shalabi D, O'Donnell M, et al.

    Journal of the American Academy of Dermatology 2021; (84(3)):615-623 doi:10.1016/j.jaad.2020.05.043.

    PMID: 32428610
  4. 4

    Evaluating the Treatment Patterns of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: By-time Reanalysis of a Randomized Controlled Phase 2 Study.

    Geskin LJ, Kim EJ, Angello JT, Kim YH

    Clinical lymphoma, myeloma & leukemia 2021; (21(2)):119-124.e4 doi:10.1016/j.clml.2020.11.022.

    PMID: 33358692
  5. 5

    Real-life experience with chlormethine gel for early-stage mycosis fungoides with emphasis on types and management of cutaneous side-effects.

    Prag Naveh H, Amitay-Laish I, Zidan O, et al.

    The Journal of dermatological treatment 2022; (33(4)):2364-2370 doi:10.1080/09546634.2021.1967266.

    PMID: 34427536
  6. 6

    Phototherapy.

    Barros NM, Sbroglio LL, Buffara MO, et al.

    Anais brasileiros de dermatologia 2021; (96(4)):397-407 doi:10.1016/j.abd.2021.03.001.

    PMID: 33849754
  7. 7

    Phototherapy as a first-line treatment for early-stage mycosis fungoides: The results of a large retrospective analysis.

    Nikolaou V, Sachlas A, Papadavid E, et al.

    Photodermatology, photoimmunology & photomedicine 2018; (34(5)):307-313 doi:10.1111/phpp.12383.

    PMID: 29533478
  8. 8

    Efficacy of narrow-band ultraviolet-B therapy in patch-stage mycosis fungoides: A clinical study and review of the literature.

    Atci T, Baykal C

    Photodermatology, photoimmunology & photomedicine 2020; (36(4)):271-277 doi:10.1111/phpp.12547.

    PMID: 32145109
  9. 9

    Comparison of Narrowband UV-B With Psoralen-UV-A Phototherapy for Patients With Early-Stage Mycosis Fungoides: A Systematic Review and Meta-analysis.

    Phan K, Ramachandran V, Fassihi H, Sebaratnam DF

    JAMA dermatology 2019; (155(3)):335-341 doi:10.1001/jamadermatol.2018.5204.

    PMID: 30698622
  10. 10

    Comparison of narrowband ultraviolet B with psoralen plus ultraviolet A phototherapy for patients with early-stage mycosis fungoides: a systematic review and meta-analysis.

    Bano S, Sidra FNU, Venjhraj FNU, et al.

    Skin health and disease 2026; (6(4)):406-414 doi:10.1093/skinhd/vzag055.

    PMID: 42539968
  11. 11

    Risk of skin cancers in mycosis fungoides patients receiving PUVA therapy: A real-life experience from a single tertiary center.

    Doğan PE, Akay BN, Vural S, et al.

    Photodermatology, photoimmunology & photomedicine 2023; (39(5)):428-434 doi:10.1111/phpp.12872.

    PMID: 36967646
  12. 12

    Syringotropic Mycosis Fungoides: A Rare Form of Cutaneous T-cell Lymphoma Enabling a Histopathologic "Sigh of Relief".

    Lehmer LM, Amber KT, de Feraudy SM

    The American Journal of dermatopathology 2017; (39(12)):920-923 doi:10.1097/DAD.0000000000000926.

    PMID: 28692463
  13. 13

    [Acrally emphasized papules-a case report].

    Marovt M, Luzar B, Marko PB

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2019; (70(1)):44-46 doi:10.1007/s00105-018-4227-1.

    PMID: 29955917
  14. 14

    Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch Cutaneous Lymphoma Group.

    van Santen S, van Doorn R, Neelis KJ, et al.

    The British journal of dermatology 2017; (177(1)):223-228 doi:10.1111/bjd.15355.

    PMID: 28132406
  15. 15

    Single-Fraction Radiation Therapy for Localized Cutaneous T-Cell Lymphoma.

    Wang P, Gilbert M, Lim HW, et al.

    Practical radiation oncology 2023; (13(4)):346-350 doi:10.1016/j.prro.2023.03.015.

    PMID: 37040819
  16. 16

    [Radiotherapy for cutaneous lymphomas].

    Rolf D, Eich HT

    Dermatologie (Heidelberg, Germany) 2022; (73(10)):772-781 doi:10.1007/s00105-022-05046-w.

    PMID: 36018330
  17. 17

    Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis.

    Kamstrup MR, Gniadecki R, Iversen L, et al.

    International journal of radiation oncology, biology, physics 2015; (92(1)):138-43.

    PMID: 25863761
  18. 18

    Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial.

    Vieyra-Garcia P, Fink-Puches R, Porkert S, et al.

    JAMA dermatology 2019; (155(5)):538-547 doi:10.1001/jamadermatol.2018.5905.

    PMID: 30892603
  19. 19

    Phototherapy as a treatment of early-stage mycosis fungoides and predictive factors for disease recurrence: A 17-year retrospective study.

    Rattanakaemakorn P, Ploydaeng M, Udompanich S, et al.

    Indian journal of dermatology, venereology and leprology 2021; (87(5)):645-650.

    PMID: 33871205

This page is for informational purposes only and does not replace professional medical advice. Your dermatologist or oncology team can help choose and monitor treatment for your specific disease.